MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
Introduction
Pancreatic cancer (PC) is a deadly disease and is considered to be among the most intractable malignancies as it is refractory to the conventional chemotherapeutics and radiation.1 Among the various genetic alterations in PC, mutation in the tumour suppressor p53 (mut-p53) gene has been reported to be about 50%.2 In the remaining 50%, the p53 is normal (wild type), but its function is inhibited by MDM2 (murine double minute 2) protein whose key role is to promote ubiquitination and proteasomal-dependent degradation of p53.3 Therapies that are based on restoring p53 function by blocking MDM2 using small molecule inhibitors (SMIs) have by far been effective in inducing growth arrest and apoptosis in cells in culture as well as in different animal model system via the activation of wt-p53 pathway.4, 5, 6 Our laboratory has been working on a new class of MDM2 inhibitors (MI-319 and MI-219) and assessing its effects on PC showing induction of cell growth inhibition, apoptosis and tumour growth arrest. However, the therapeutic applicability of blocking MDM2 by such inhibitors including Nutlin-3 has been focused on its activity in wt-p53 tumours and very modest information is available on the role of other MDM2-regulated proteins such as the role of p73 especially in PC. Interestingly, recent evidences suggest that all p53 family proteins may cooperate in preventing tumour formation and this is proven by the observation that p63- and p73-deficient cells are resistant to p53-induced apoptosis.7, 8, 9
P73 appears to be an important protein, which is also under the influence of MDM2 and shares a high degree of sequence homology to p53.10 Although p73 has been implicated in developmental biology, there is ample evidence suggesting that, at least in part, the function of p73 may closely resemble that of p53.11, 12 Indeed, like p53, p73 induces G1 cell growth arrest, activates the transcription of some endogenous p53 target genes such as p21Waf1/Cip1, mdm2, bax, cyclin G13, 14, 15 and induces apoptosis irrespective of p53 status.1, 4 Most significantly, p73 has been shown to be a key determinant of cellular sensitivity to anticancer therapeutics, and is widely induced by chemotherapeutic agents in a variety of tumour cell lines particularly in tumours lacking p53.16 Several studies have shown that p73 is activated by DNA-damaging agents, including anthracyclines, topoisomerase I inhibitors and cisplatin.17, 18, 19, 20 Importantly, not all cells demonstrate the activation of p73 in response to each of these DNA-damaging agents, and thus the p73-dependent response to drugs is likely dependent on the cellular context including the presence or absence of functional p53. Among chemotherapeutic agents, cisplatin, docetaxel (Taxotere) and doxorubicin (Adriamycin) have been frequently used for the treatment of cancers including prostate, breast, lung and pancreatic cancers, alone or in combination with other agents.21, 22, 23, 24, 25 Several clinical trials have reported that these agents, used in combination with other drugs, show improved outcomes in objective response rates and survival in pancreatic cancer (El-Reyes and Philip 2003).26 Since both p53 and p73 have been implicated in cell response to cisplatin, the aim of the present study was to explore role of p73 in MDM2 inhibitor-cisplatin mediated anti-tumour effects in PC cells lacking functional p53 than in PC cells having wt-p53.
Section snippets
Cell culture, experimental reagents and chemicals
Human PC cell lines Capan-2, BxPC-3, Colo-357 and Panc-28 were purchased from ATCC. The cell lines have been tested and authenticated in core facility Applied Genomics Technology Center at Wayne State University on 13th March 2009. The method used for testing was short tandem repeat (STR) profiling using the PowerPlex® 16 System from Promega (Madison, WI). Primary antibodies for p53, p73 and p21 were purchased from Cell Signaling. All secondary antibodies were obtained from Sigma (Saint Louis).
MI-319-mediated effects on PC cells were enhanced by cisplatin in reducing cell viability and inhibition of cell growth/survival irrespective of p53 function
The combination studies of MI-319 with cisplatin have never been done on PC cells with mut-p53, we therefore tested whether MI-319 could synergize with cisplatin leading to enhanced suppression of cell viability and survival as assessed by trypan blue, MTT and clonogenic assays. As can be seen from the results of Fig. 1A in Panc-28 and colo-357 cells MI-319 or cisplatin (at 15 μM and 1 μM, respectively) alone did not induce any appreciable loss of cell viability (only 10-15% in Panc-28 and
Discussion
To our knowledge this is the first report showing activity of MDM2 inhibitor in combination with cisplatin against PC cells irrespective of p53 status. The ability of p73 to be up-regulated by MDM2-cisplatin combination and mediating the p53-independent anti-tumour effects could be a reflection of its more pervasive role compared to mutant p53 in pancreatic tumourigenesis than has currently been believed. Our interesting and novel animal studies and supportive in vitro data provide confidence
Conflict of interest statement
The University of Michigan has filed a patent on MI-319, which has been licensed by Ascenta Therapeutics Inc. The University of Michigan and S. Wang and Dajun Yang own equity in Ascenta.
Acknowledgements
National Cancer Institute, NIH Grant R01CA109389 (R.M. Mohammad), NIH Grant 5R01CA101870 (F.H. Sarkar) and NIH Grant U19CA113317 (S. Wang). We sincerely acknowledge the Guido foundation for their support.
References (42)
- et al.
Structural details on mdm2–p53 interaction
J Biol Chem
(2005) - et al.
P63 and p73 are not required for the development and p53-dependent apoptosis of T cells
Cancer Cell
(2004) - et al.
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
Cell
(1997) - et al.
On the shoulders of giants: p63, p73 and the rise of p53
Trends Genet
(2002) - et al.
Chemosensitivity linked to p73 function
Cancer Cell
(2003) - et al.
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop
Mol Cell
(2008) - et al.
Any progress in the management of advanced pancreatic cancer?
JOP
(2009) - et al.
p53 protein expression as prognostic factor in human pancreatic cancer
Anticancer Res
(1997) - et al.
Therapeutic potential of mdm2 inhibition in malignant germ cell tumours
Eur Urol
(2009) - et al.
The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies
Curr Pharm Des
(2008)
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma
Clin Cancer Res
The roles of p63 in cancer
Cell Cycle
P63 and p73 are required for p53-dependent apoptosis in response to DNA damage
Nature
P63 and P73: P53 mimics, menaces and more
Nat Rev Mol Cell Biol
P73 is a simian correction of human p53-related protein that can induce apoptosis
Nature
P63 expression profiles in human normal and tumor tissues
Clin Cancer Res
P73 function is inhibited by tumor-derived p53 mutants in mammalian cells
Mol Cell Biol
P73: regulator in cancer and neural development
Cell Death Differ
Family feud in chemosensitvity: p73 and mutant p53
Cell Cycle
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Nature
Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin
Proc Natl Acad Sci USA
Cited by (62)
Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53
2023, Biochimica et Biophysica Acta - Reviews on CancerThe potential roles of p53 signaling reactivation in pancreatic cancer therapy
2022, Biochimica et Biophysica Acta - Reviews on CancerRecommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
2020, Annals of OncologyCitation Excerpt :As we mentioned for other tumours, patients with MSI-H and NTRK fusion-positive tumours presented meaningful clinical benefit with matched therapies in multi-histology studies.50,97,114,115 Several additional alterations are classified at high level according to ESCAT in other tumours, but have not yet shown a significant impact in pancreatic cancer like KRAS, PIK3CA, BRAFV600E mutations, MDM2, ERBB2 amplifications and NRG1, ALK, RET, ROS1 fusions.55,91,116–125 The main drivers of PDAC and their classification are described in Table 8.
PPIs as therapeutic targets for anticancer drug discovery: the case study of MDM2 and BET bromodomain inhibitors
2019, Small Molecule Drug Discovery: Methods, Molecules and ApplicationsReactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment
2019, Biomedicine and PharmacotherapyCitation Excerpt :MDM2 E3 ligase inhibitors: The first MDM2 E3 ligase inhibitors was discovered in 2002 and concerns the arylsulfonamide, bisarylurea, and acylimidazolone which were discovered in an MDM2-mediated p53 ubiquitinylation screening of a chemical library [71]. After two years, family of closely related 7-nitro-5-deazaflavin compounds called HLI98 were identified as inhibitors of MDM2 E3 ubiquitin ligase activity.